Skip to main content

Evotec Value Stock - Dividend - Research Selection

Evotec

ISIN: DE0005664809, WKN: 566480

Market price date: 17.05.2022
Market price: 24,87 EUR


Evotec Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 08-05-2022
Cash flow
Net operating cash flow 122.240.000
Capital Expenditures -118.940.000
Free cash flow 3.300.000
Balance sheet
Total Equity 1.378.000.000
Liabilities & Shareholders equity 2.276.000.000
Income statement
Net income 215.510.000
Eps (diluted) 1,290
Diluted shares outstanding 164.000.000
Net sales/revenue 618.030.000

Fundamental ratios calculated on: 17-05-2022

Ratios
Key figures 17-05-2022
Cash flow
P/C 33,37
   
P/FC 1.235,96
Balance sheet
ROI9,47
ROE60,55
Income statement
P/E19,28
Div. Yield0,00%
P/B2,96
P/S6,60


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolEVT.XETRA
Market Capitalization4.946.852.864,00 USD
CountryGermany
IndicesCDAX,HDAX,MDAX,Prime All Share,STOXX EUROPE 600,TecDAX
SectorsHealth Care Technology
Raw Data SourceIFRS in Millionen EUR
Stock Split2005-06-10,846.000000/841.000000; 2000-08-18,2.0000/1.0000
Internetwww.evotec.com


Description of the company

Evotec AG is a Germany-based parent company of the Evotec group, which is engaged in drug discovery and development company focused on providing integrated drug discovery services and alliances to the pharmaceutical and biotechnology industry. In addition, the Company has a small number of its own drug candidates at various stages of development either partnered or available for partnering. It provides integrated solutions to the pharmaceutical and biotechnology industry from target to clinical development through a range of capabilities and capacities, including early-stage assay development and screening, fragment-based drug discovery through to medicinal chemistry and in vivo and in vitro pharmacology. As of December 31, 2011, its primary operating entities included the United Kingdom-based Evotec (UK) Ltd, India-based Evotec (India) Private Ltd, the United States-based Compound Focus, Inc, and two Germany-based subsidiaries Kinaxo Biotechnologies GmbH and DeveloGen AG

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.evotec.com


NEWS